The Metastatic Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Bile Duct Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Bile Duct Cancer and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Metastatic Bile Duct Cancer by ten companies/universities/institutes. The top development phase for Metastatic Bile Duct Cancer is phase ii with six drugs in that stage. The Metastatic Bile Duct Cancer pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Metastatic Bile Duct Cancer pipeline products market are: Boehringer Ingelheim International, Les Laboratoires Servier and MacroGenics.
The key targets in the Metastatic Bile Duct Cancer pipeline products market include Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1), and Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1).
The key mechanisms of action in the Metastatic Bile Duct Cancer pipeline product include Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Inhibitor with two drugs in Pre-Registration. The Metastatic Bile Duct Cancer pipeline products include two routes of administration with the top ROA being Oral and four key molecule types in the Metastatic Bile Duct Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Metastatic Bile Duct Cancer overview
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool or dark urine may also occur.
For a complete picture of Metastatic Bile Duct Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
